Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

“FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is actually seeking such exclusivity,” according to legislative proposals document.

Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.

Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.